Andrx’ Florida Manufacturing Operations Subject Of Second FDA-483 Notice

FDA has provided “conflicting information” about whether GMP issues will delay ANDA approvals, Andrx says. The company is slated to meet with FDA in the next 60 days to discuss implementation of a corrective action plan that would address Form 483 observations issued in March and July.